IL-17 inhibitors will drive psoriatic arthritis market to $12.6 billion by 2025

The psoriatic arthritis market across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, the UK, and Japan, is set to grow from $4.53 billion in 2015 to around $12.6 billion by 2025, at a compound annual growth rate of 10.74%,

According to research and consulting firm GlobalData’s latest report, the relatively strong growth will primarily be driven by the increase in diagnosed prevalent cases. The launches of interleukin (IL)-17 inhibitors, such as Eli Lilly’s (NYSE: LLY) Taltz (ixekizumab) and AstraZeneca’s (LSE: AZN) Lumicef (brodalumab), as well as Celgene’s (Nasdaq: CELG) oral therapy Otezla (apremilast), will also drive the market, and will provide more treatment options for physicians.

Alexandra Annis, GlobalData’s analyst covering immunology, explains: “Reasons for the increased diagnosed cases of psoriatic arthritis include better awareness of the disease due to educational campaigns and an interdisciplinary approach to managing the condition between dermatologists and rheumatologists. As such, the number of total treated cases in the 7MM is expected to increase from around 770,000 in 2015 to almost 1.2 million by 2025.”